Increased risk of breakthrough SARS-CoV-2 infection with ChAdOx1 compared to BNT162b2 vaccine

increased risk of breakthrough sars cov 2 infection with chadox1 compared to bnt162b2 vaccine

Sumary of Increased risk of breakthrough SARS-CoV-2 infection with ChAdOx1 compared to BNT162b2 vaccine:

  • Study: Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort.
  • however, 79% of recent coronavirus disease 2019 (COVID-19) deaths in the U.K. have occurred as a result of breakthrough infections in double vaccinated individuals at least 14 days prior to the positive SARS-CoV-2 test.
  • Given the high levels of breakthrough infections and subsequent deaths occurring in double vaccinated individuals, it is important to understand trajectories of anti-S waning in individuals after they have received their second dose of the COVID- 19 vaccine.
  • Furthermore, it is important to determine whether the timing of their second dose can be used as a correlate of protection for SARS-CoV-2 infection in an effort to inform vaccine policies around the world.
  • A total of 24,049 samples from 8,858 individuals, 5,549 of whom received a second dose of ChAdOx1 and 3,205 received BNT162b2 vaccines, who remained anti-nucleocapsid (anti-N) antibody negative, were included in the analysis of anti-S waning over time.
  • Anti-S level, a meaningful correlate of protection against SARS-Cov-2 infection Related StoriesIn total, data from 8,275 individuals were analyzed for anti-S levels prior to breakthrough infection to examine anti-S as a correlate of protection against SARS-Cov-2 infection.
  • During the timeline for this particular study, the team observed 197 breakthrough infection cases.
  • Further, they found that individuals with anti-S levels less than 500 U/ml following the second dose were nearly twice as likely to experience a breakthrough infection compared to those with higher levels.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.